Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy and Surgery for Unresectable Infant Neuroblastoma (INES 99.1)
NCT00025597Phase 2Completed
- Sponsor
- European Infant Neuroblastoma Study Group
- Start
- Jul 1999
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of vincristine, cyclophosphamide, etoposide, carboplatin and doxorubicin in neuroblastoma (2 arms), sponsored by European Infant Neuroblastoma Study Group. Primary endpoints: Survival at 5 years and Morbidity at 5 years. Started Jul 1999; status: completed.
02
Drugs
vincristinecyclophosphamideetoposidecarboplatindoxorubicin
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00025597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025597.